Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA - Wikidata - wikimedia - TriplyDB

Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA

Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA

http://www.wikidata.org/entity/Q35101408

about

An ImmunoChip study of multiple sclerosis risk in African Americans.Multiple sclerosis susceptibility alleles in African Americans.Refining the association of MHC with multiple sclerosis in African Americans.The importance of HLA DRB1 gene allele to clinical features and disability in patients with multiple sclerosis in Lithuania Vitamin D in African Americans with multiple sclerosis.Multiple sclerosis in US minority populations: Clinical practice insights.MS in South Asians in England: early disease onset and novel pattern of myelin autoimmunity.Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study Genetic determinants of risk and progression in multiple sclerosis.Neurocognitive sequelae in African American and Caucasian children with multiple sclerosis.Progress in multiple sclerosis genetics.The immunogenetics of multiple sclerosis: A comprehensive review.Complex relation of HLA-DRB1*1501, age at menarche, and age at multiple sclerosis onset.Genetic risk variants in African Americans with multiple sclerosis Spinal cord lesions and disability in Hispanics with multiple sclerosis.Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis.The killer immunoglobulin-like receptor KIR3DL1 in combination with HLA-Bw4 is protective against multiple sclerosis in African Americans First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.A critical appraisal of treatment decisions in multiple sclerosis--old versus new.The genetics of multiple sclerosis: an up-to-date review.Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate.Admixture mapping: from paradigms of race and ethnicity to population history.An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people.Opposing effects of the HLA-DRB1*0301-DQB1*0201 haplotype on the risk for multiple sclerosis in diverse Arab populations in Israel.Effect of gender on late-onset multiple sclerosis.Cerebral Gray Matter Atrophy Is Associated with the CSF IgG index in African American with Multiple Sclerosis.SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.The Gut Microbiome in Neuromyelitis Optica.Differential Impact of Multiple Sclerosis on Cortical and Deep Gray Matter Structures in African Americans and Caucasian Americans.HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population.

P2860

Q30300285-D006F5D4-3724-4E85-A4E7-AAB2E7E60CEE Q33892035-534FA566-7D13-4585-884C-4D56C647CC58 Q33980298-8484AC88-6BAE-4013-87F2-13CE5FC15A8C Q34803260-AE216402-CAE6-4D52-A67A-60B6C645EFF5 Q34999315-1598C45E-D70E-4E0B-81AD-69D78C4F02B7 Q35500198-3AD9168E-47E3-4FBB-8230-98668DDBD410 Q35601282-DB95FD1D-1A53-4E55-83DD-72FAB779D08B Q35722940-16A0D2A0-1BDE-4DF1-8DBE-AD0E76E53F9F Q35915818-514E0896-B62F-4ADB-9E79-A6759D748D6C Q36064719-F4B4C5FF-8EB9-4C90-9E66-C1A5362C955B Q36382352-9EE1053C-B398-46B3-99B0-97DD33A843C4 Q36394834-A0022A77-2396-4AAF-A03A-18EE7E302F2B Q37129595-6C96C945-FE70-4D95-839C-29AFCBF2CE22 Q37163271-39BE9931-1626-4878-9F53-01118A3F23A6 Q37275133-85801B1C-9F6E-4EB4-BF52-1937D8C96A9F Q37343648-859756B8-12FA-4531-B824-FFEAC8303F5F Q37409286-833D1C33-4301-42C7-A2CE-CE323988125C Q37588251-6EC2BA69-A09B-4028-A7EE-D80A3762C1A8 Q37862062-E439332C-52B8-4F6C-AC12-A05ACF283907 Q38020959-597E2903-12E3-4049-B77B-6090526A29A0 Q38600432-586058B6-3B72-4A7D-BAED-31023FCC526A Q39763124-3D9F0691-4766-415F-938A-459EB0D18E08 Q43136367-30B201BD-2F19-4568-9251-42CC238CF64E Q43504710-B9679A1F-E084-4ABD-A975-33314B959E9B Q44916829-2ADA9FC6-76DF-463E-8024-0EF167C35779 Q46159575-041BA731-750B-42A0-AE19-8287B1145023 Q46861116-B2BE068F-9137-4FBD-B5A0-E415376A9822 Q47252742-29A5E126-5DF7-489E-8CC1-BDD95A8DB12B Q48510335-A20DB6E2-B2CC-4C00-A5C5-8F654FA4BC33 Q54419877-C2E71BAE-D313-4D76-88A4-A9556E0A8780

P2860

Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA

http://www.wikidata.org/entity/Q35101408

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA

@ast

Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA

@en

type

label

Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA

@ast

Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA

@en

prefLabel

Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA

@ast

Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA

@en

P1433

Q35101408-C2032BE6-B635-4E92-963F-50627E1B725F

P1476

Q35101408-A12F1BE4-2977-4C9F-BFAD-0524C1F63B4C

P2093

Q35101408-08438A5D-C1BC-41CD-88C7-423151A9A008

Q35101408-2514A0D0-C8FA-4BBC-B4E3-19CB3E465676

Q35101408-44881B6E-187D-45D0-839E-F98AE50AA7D9

Q35101408-588E8F2C-4100-4F6B-A380-3D1C4BE71BDD

Q35101408-63E75ED3-4A43-4982-9D4B-2AF7E744B01A

Q35101408-68414E49-8AA6-4D9C-A2C0-BEF2B74234BD

Q35101408-DC3EA92B-AA08-4B28-A389-CF1039545CEC

Q35101408-EA0E8BDE-0E78-435D-B1F1-28DD17F4D29D

Q35101408-FDF34C97-8099-4A3C-8FFA-8B1331D7ECF5

P2860

Q35101408-00A83DDB-4E6D-4A65-9B40-3FEF1145D0D5

Q35101408-0D12F35C-B34E-4D5A-9ACF-E82511666CF1

Q35101408-0F1E195F-9BF3-4621-BFCF-EF68E6F31DCF

Q35101408-10E67EE0-5831-4C3C-B92A-470BAAF0C9FF

Q35101408-1195988B-74B4-485F-9A21-8094021DE659

Q35101408-13F38925-6993-45ED-B156-F007720CA914

Q35101408-15A11915-55EB-40FE-AC58-5712834EF501

Q35101408-18467E3C-992C-4068-8C5D-1DCC25C9B458

Q35101408-2F68C560-75E7-4C84-A735-6158C53C1CC2

Q35101408-3D7A20ED-3D92-4B10-86BF-712F4769F30B

P304

Q35101408-64314815-6DBB-41FE-BFE1-31E011BFDD93

P31

Q35101408-72C8A23F-9167-482E-B4A3-1F6826859359

P356

Q35101408-0FC530F0-3D3A-4D30-984E-5F7F03380613

P433

Q35101408-BB7E8CDB-E40C-4C48-9F19-2530B735E564

P478

Q35101408-DD0852BA-908C-41AE-B662-A6377E16521B

P50

Q35101408-F2F33013-C73E-4317-BDA9-EAFBD08F81D6

P577

Q35101408-8E12163D-A23C-4B6F-8D32-EEDB0AF8EF58

P5875

Q35101408-9370CE78-29A4-4EC3-83DC-C4821AFDBD0C

P698

Q35101408-645BD231-9B0C-418C-9230-898457AB5BA4

P921

Q35101408-E091F096-4B98-4E75-9B65-B228FBF61312

P932

Q35101408-8CFF88AB-6F1B-48C9-9F15-D49E049CE8C8

P356

ARCHNEUROL.2008.541

P1433

P1476

Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA

@en

P2093

Amit Bar-Or

http://www.w3.org/2001/XMLSchema#string

Bruce A C Cree

http://www.w3.org/2001/XMLSchema#string

Christine Tong

http://www.w3.org/2001/XMLSchema#string

David E Reich

http://www.w3.org/2001/XMLSchema#string

Jorge R Oksenberg

http://www.w3.org/2001/XMLSchema#string

Omar Khan

http://www.w3.org/2001/XMLSchema#string

Philip L De Jager

http://www.w3.org/2001/XMLSchema#string

Stephen L Hauser

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Takahashi

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

How common are the "common" neurologic disorders?

Methods for high-density admixture mapping of disease genes

Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans.

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatm

Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis

Risk alleles for multiple sclerosis identified by a genomewide study

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

P304

226-233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUROL.2008.541

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Ichiro Nakashima

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23994580

http://www.w3.org/2001/XMLSchema#string

P698

19204159

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

4334456

http://www.w3.org/2001/XMLSchema#string